Criteria for nocturnal polyuria in nocturnal enuresis

Abstract. This study examined the hypothesis that nocturnal enuresis might be paralleled by aquaporin 2 (AQP2) urinary excretion. Eighty children who experienced nocturnal enuresis were studied and compared with 9 healthy children. The 24-h urine samples were divided into two portions: night collections and day collections. Creatinine equivalents of urine samples from each patient were analyzed by Western blotting. AQP2 levels were semiquantified by densitometric scanning and reported as a ratio between the intensity of the signal in the day urine sample versus the night urine sample (D/N AQP2 ratio). The D/N AQP2 ratio was 0.59 ± 0.11 (n = 9) in healthy children and increased to 1.27 ± 0.24 (n = 10) in a subpopulation of enuretic children who had low nocturnal vasopressin levels. In enuretic children who displayed hypercalciuria and had normal vasopressin levels, the D/N AQP2 ratio was 1.05 ± 0.27 (n = 8). These data indicate that reduced secretion of vasopressin and absorptive hypercalciuria are independently associated with an approximately twofold increase in the urinary D/N AQP2 ratio. When low nocturnal vasopressin levels were associated with hypercalciuria, a nearly threefold increase in the D/N AQP2 ratio was observed (1.67 ± 0.41, n = 11). In addition, in all enuretic patients tested, the urinary D/N AQP2 ratio correlates perfectly with the severity of the disorder (nocturnal polyuria). The findings reported in this article indicate that urinary AQP2 correlates with the severity of enuresis in children.

Download Full-text

Biomarkers in Urine for Children With Monosymptomatic Nocturnal Enuresis and Nocturnal Polyuria

Case Medical Research ◽

10.31525/ct1-nct04049019 ◽

2019 ◽

Author(s):

Keyword(s):

Nocturnal Enuresis ◽

Nocturnal Polyuria ◽

Monosymptomatic Nocturnal Enuresis

Download Full-text

Faculty Opinions recommendation of Nocturnal polyuria and nocturnal arginine vasopressin (AVP): a key factor in the pathophysiology of monosymptomatic nocturnal enuresis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164582.626362 ◽

2009 ◽

Author(s):

Howard Snyder ◽

Steve Kim

Keyword(s):

Arginine Vasopressin ◽

Nocturnal Enuresis ◽

Nocturnal Polyuria ◽

Key Factor ◽

Monosymptomatic Nocturnal Enuresis

Download Full-text

Desmopressin 120 mcg, 180 mcg, 240 mcg: The right treatment for the right patient

Archivio Italiano di Urologia e Andrologia ◽

10.4081/aiua.2018.2.127 ◽

2018 ◽

Vol 90 (2) ◽

pp. 127 ◽

Cited By ~ 3

Author(s):

Pietro Ferrara ◽

Ester Del Vescovo ◽

Francesca Ianniello ◽

Giulia Franceschini ◽

Luciana Romaniello ◽

...

Keyword(s):

Drug Therapy ◽

Nocturnal Enuresis ◽

Bladder Function ◽

Efficacy And Safety ◽

Nocturnal Polyuria ◽

First Line ◽

Normal Bladder ◽

Increased Risk ◽

The Right ◽

Line Drug

Background: The first-line drug therapy for patients with nocturnal enuresis (NE) associated with nocturnal polyuria and normal bladder function is desmopressin (dDAVP). Objective: To evaluate if increasing dose of oral desmopressin lyophilisate (MELT) can improve response rates to dDAVP and is useful in enuretic children. Materials and methods: We enrolled a total of 260 children all diagnosed with NE. Enuretic children were treated with increasing MELT at a dose of 120, 180 and 240 mcg a day.Results. We included in our study a total of 237 children, 164 males (69.2%) and 73 females (30.8%) aged between 5 and 18 years (mean age 10.32 ± 2.52 years). Of the 237 patients enrolled in the study and treated with MELT 120 mcg, a full response was achieved in 135 (56.9%). A partial response was achieved in 21 (8.9%) patients, therefore the dose was increased up to 180 mcg, with further improving symptoms (14.3%) or full response (9.5%), and up to 240 mcg, without usefulness. Conclusions: MELT at the dose of 120 mcg resulted efficacy and safety; the increased dose up to 180 mcg resulted poorly efficacy; finally, the further increase up to 240 mcg did not improve the symptoms with the increased risk of side effects.

Download Full-text